Skip to main content

Advertisement

SpringerLink
Log in

Non-functional Pancreatic Neuroendocrine Tumor as an Incidentaloma—A Case Report and Review of Literature

  • Case Report
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9(1):61–72.

    Article  PubMed  CAS  Google Scholar 

  2. Kang CM, Park SH, Kim KS, Choi JS, Lee WJ, Kim BR. Surgical experiences of functioning neuroendocrine neoplasm of the pancreas. Yonsei Med J. 2006;47(6):833–9.

    Article  PubMed  Google Scholar 

  3. Massironi S, Sciola V, Peracchi M, Ciafardini C, Spampatti MP, Conte D. Neuroendocrine tumors of the gastro-entero-pancreatic system. World J Gastroenterol. 2008;14(35):5377–84.

    Article  PubMed  Google Scholar 

  4. Kulke MH, Anthony LB, Bushnell DL, de Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas. 2010;39(6):735–52.

    Article  PubMed  Google Scholar 

  5. Oberg K, Eriksson B. Endocrine tumours of the pancreas. Best Pract Res Clin Gastroenterol. 2005;19(5):753–81.

    Article  PubMed  Google Scholar 

  6. Kloppel G, Anlauf M. Epidemiology, tumour biology and histopathological classification of neuroendocrine tumours of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2005;19(4):507–17.

    Article  PubMed  Google Scholar 

  7. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008;135(5):1469–92.

    Article  PubMed  CAS  Google Scholar 

  8. Kimura W, Kuroda A, Morioka Y. Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases. Dig Dis Sci. 1991;36(7):933–42.

    Article  PubMed  CAS  Google Scholar 

  9. Ehehalt F, Saeger HD, Schmidt CM, Grutzmann R. Neuroendocrine tumors of the pancreas. Oncologist. 2009;14(5):456–67.

    Article  PubMed  CAS  Google Scholar 

  10. Falconi M, Plockinger U, Kwekkeboom DJ, Manfredi R, Korner M, Kvols L, et al. Well-differentiated pancreatic nonfunctioning tumors/carcinoma. Neuroendocrinology. 2006;84(3):196–211.

    Article  PubMed  CAS  Google Scholar 

  11. O’Toole D, Salazar R, Falconi M, Kaltsas G, Couvelard A, de Herder WW, et al. Rare functioning pancreatic endocrine tumors. Neuroendocrinology. 2006;84(3):189–95.

    Article  PubMed  Google Scholar 

  12. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 Suppl):1807–43.

    Article  PubMed  Google Scholar 

  13. Gibril F, Schumann M, Pace A, Jensen RT. Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine (Baltimore). 2004;83(1):43–83.

    Article  Google Scholar 

  14. Plockinger U, Wiedenmann B. Diagnosis of non-functioning neuro-endocrine gastro-enteropancreatic tumours. Neuroendocrinology. 2004;80 Suppl 1:35–8.

    Article  PubMed  Google Scholar 

  15. Gullo L, Migliori M, Falconi M, Pederzoli P, Bettini R, Casadei R, et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol. 2003;11:2435–9.

    Article  Google Scholar 

  16. Ong SL, Garcea G, Pollard CA, Furness PN, Steward WP, Rajesh A, et al. A fuller understanding of pancreatic neuroendocrine tumours combined with aggressive management improves outcome. Pancreatology. 2009;9(5):583–600.

    Article  PubMed  CAS  Google Scholar 

  17. Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab. 2007;21(1):43–68.

    Article  PubMed  CAS  Google Scholar 

  18. Noone TC, Hosey J, Firat Z, Semelka RC. Imaging and localization of islet-cell tumours of the pancreas on CT and MRI. Best Pract Res Clin Endocrinol Metab. 2005;19(2):195–211.

    Article  PubMed  Google Scholar 

  19. Sundin A, Vullierme MP, Kaltsas G, Plockinger U. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: radiological examinations. Neuroendocrinology. 2009;90(2):167–83.

    Article  PubMed  CAS  Google Scholar 

  20. Sundin A, Garske U, Orlefors H. Nuclear imaging of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):69–85.

    Article  PubMed  CAS  Google Scholar 

  21. Gibril F, Jensen RT. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroenteropancreatic endocrine tumours. Dig Liver Dis. 2004;36 Suppl 1:S106–20.

    Article  PubMed  CAS  Google Scholar 

  22. Virgolini I, Traub-Weidinger T, Decristoforo C. Nuclear medicine in the detection and management of pancreatic islet-cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19(2):213–27.

    Article  PubMed  Google Scholar 

  23. McLean AM, Fairclough PD. Endoscopic ultrasound in the localisation of pancreatic islet cell tumours. Best Pract Res Clin Endocrinol Metab. 2005;19(2):177–93.

    Article  PubMed  CAS  Google Scholar 

  24. Norton JA, Jensen RT. Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg. 2004;240(5):757–73.

    Article  PubMed  Google Scholar 

  25. Doppman JL, Miller DL, Chang R, Maton PN, London JF, Gardner JD, et al. Gastrinomas: localization by means of selective intraarterial injection of secretin. Radiology. 1990;174(1):25–9.

    PubMed  CAS  Google Scholar 

  26. Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995;123(4):269–73.

    Article  PubMed  CAS  Google Scholar 

  27. Orlefors H, Sundin A, Garske U, Juhlin C, Oberg K, Skogseid B, et al. Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography. J Clin Endocrinol Metab. 2005;90(6):3392–400.

    Article  PubMed  CAS  Google Scholar 

  28. Eriksson B, Orlefors H, Oberg K, Sundin A, Bergstrom M, Langstrom B. Developments in PET for the detection of endocrine tumours. Best Pract Res Clin Endocrinol Metab. 2005;19(2):311–24.

    Article  PubMed  CAS  Google Scholar 

  29. Shin LK, Brant-Zawadzki G, Kamaya A, Jeffrey RB. Intraoperative ultrasound of the pancreas. Ultrasound Q. 2009;25(1):39–48. quiz 48.

    Article  PubMed  Google Scholar 

  30. Gibril F, Doppman JL, Reynolds JC, Chen CC, Sutliff VE, Yu F, et al. Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol. 1998;16(3):1040–53.

    PubMed  CAS  Google Scholar 

  31. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996;125(1):26–34.

    Article  PubMed  CAS  Google Scholar 

  32. Termanini B, Gibril F, Reynolds JC, Doppman JL, Chen CC, Stewart CA, et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management. Gastroenterology. 1997;112(2):335–47.

    Article  PubMed  CAS  Google Scholar 

  33. Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol. 2000;95(9):2271–7.

    Article  PubMed  CAS  Google Scholar 

  34. Kann PH, Balakina E, Ivan D, Bartsch DK, Meyer S, Klose KJ, et al. Natural course of small, asymptomatic neuroendocrine pancreatic tumours in multiple endocrine neoplasia type 1: an endoscopic ultrasound imaging study. Endocr Relat Cancer. 2006;13(4):1195–202.

    Article  PubMed  CAS  Google Scholar 

  35. Langer P, Kann PH, Fendrich V, Richter G, Diehl S, Rothmund M, et al. Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg. 2004;28(12):1317–22.

    Article  PubMed  Google Scholar 

  36. Libutti SK, Choyke PL, Bartlett DL, Vargas H, Walther M, Lubensky I, et al. Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery. 1998;124(6):1153–9.

    Article  PubMed  CAS  Google Scholar 

  37. Akerstrom G, Hellman P. Surgery on neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):87–109.

    Article  PubMed  Google Scholar 

  38. Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res. 2004;120(1):139–61.

    Article  PubMed  CAS  Google Scholar 

  39. Triponez F, Goudet P, Dosseh D, Cougard P, Bauters C, Murat A, et al. Is surgery beneficial for MEN1 patients with small (< or = 2 cm), nonfunctioning pancreaticoduodenal endocrine tumor? An analysis of 65 patients from the GTE. World J Surg. 2006;30(5):654–62. discussion 663-654.

    Article  PubMed  Google Scholar 

  40. Norton JA, Fraker DL, Alexander HR, Venzon DJ, Doppman JL, Serrano J, et al. Surgery to cure the Zollinger-Ellison syndrome. N Engl J Med. 1999;341(9):635–44.

    Article  PubMed  CAS  Google Scholar 

  41. Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg. 2006;10(3):327–31.

    Article  PubMed  Google Scholar 

  42. Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, et al. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17(6):1621–7.

    Article  PubMed  Google Scholar 

  43. Barakat MT, Meeran K, Bloom SR. Neuroendocrine tumours. Endocr Relat Cancer. 2004;11(1):1–18.

    Article  PubMed  CAS  Google Scholar 

  44. La Rosa S, Klersy C, Uccella S, Dainese L, Albarello L, Sonzogni A, et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol. 2009;40(1):30–40.

    Article  PubMed  Google Scholar 

  45. Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18(5):947–55.

    PubMed  Google Scholar 

  46. Dralle H, Krohn SL, Karges W, Boehm BO, Brauckhoff M, Gimm O. Surgery of resectable nonfunctioning neuroendocrine pancreatic tumors. World J Surg. 2004;28(12):1248–60.

    Article  PubMed  Google Scholar 

  47. Park BJ, Alexander HR, Libutti SK, Huang J, Royalty D, Skarulis MC, et al. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery. 1998;124(6):1056–61. discussion 1061-1052.

    Article  PubMed  CAS  Google Scholar 

  48. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery. 2001;130(6):1078–85.

    Article  PubMed  CAS  Google Scholar 

  49. Vilar E, Salazar R, Perez-Garcia J, Cortes J, Oberg K, Tabernero J. Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer. 2007;14(2):221–32.

    Article  PubMed  CAS  Google Scholar 

  50. Pape UF, Jann H, Muller-Nordhorn J, Bockelbrink A, Berndt U, Willich SN, et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer. 2008;113(2):256–65.

    Article  PubMed  Google Scholar 

  51. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006;449(4):395–401.

    Article  PubMed  CAS  Google Scholar 

  52. Ferrone CR, Tang LH, Tomlinson J, Gonen M, Hochwald SN, Brennan MF, et al. Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified? J Clin Oncol. 2007;25(35):5609–15.

    Article  PubMed  Google Scholar 

  53. Fendrich V, Waldmann J, Bartsch DK, Langer P. Surgical management of pancreatic endocrine tumors. Nat Rev Clin Oncol. 2009;6(7):419–28.

    Article  PubMed  Google Scholar 

  54. Dimou AT, Syrigos KN, Saif MW. Neuroendocrine tumors of the pancreas: what’s new. Highlights from the “2010 ASCO Gastrointestinal Cancers Symposium”. Orlando, FL, USA. JOP. 2010;11(2):135–8.

    PubMed  Google Scholar 

  55. Steinmuller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2008;87(1):47–62.

    Article  PubMed  Google Scholar 

  56. O’Toole D, Ruszniewski P. Chemoembolization and other ablative therapies for liver metastases of gastrointestinal endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19(4):585–94.

    Article  PubMed  Google Scholar 

  57. Gulec SA, Mesoloras G, Dezarn WA, McNeillie P, Kennedy AS. Safety and efficacy of Y-90 microsphere treatment in patients with primary and metastatic liver cancer: the tumor selectivity of the treatment as a function of tumor to liver flow ratio. J Transl Med. 2007;5:15.

    Article  PubMed  Google Scholar 

  58. Moertel CG, Lefkopoulo M, Lipsitz S, Hahn RG, Klaassen D. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med. 1992;326(8):519–23.

    Article  PubMed  CAS  Google Scholar 

  59. Norton JA, Melcher ML, Gibril F, Jensen RT. Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery. 2004;136(6):1267–74.

    Article  PubMed  Google Scholar 

  60. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol. 2004;22(23):4762–71.

    Article  PubMed  CAS  Google Scholar 

  61. Toumpanakis C, Meyer T, Caplin ME. Cytotoxic treatment including embolization/chemoembolization for neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab. 2007;21(1):131–44.

    Article  PubMed  CAS  Google Scholar 

  62. Moertel CG, Kvols LK, O’Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991;68(2):227–32.

    Article  PubMed  CAS  Google Scholar 

  63. Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res. 2009;15(1):338–45.

    Article  PubMed  CAS  Google Scholar 

  64. Ramanathan RK, Cnaan A, Hahn RG, Carbone PP, Haller DG. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol. 2001;12(8):1139–43.

    Article  PubMed  CAS  Google Scholar 

  65. Arnold R, Rinke A, Schmidt C, Hofbauer L. Endocrine tumours of the gastrointestinal tract: chemotherapy. Best Pract Res Clin Gastroenterol. 2005;19(4):649–56.

    Article  PubMed  CAS  Google Scholar 

  66. Dirix LY, Vermeulen PB, Fierens H, De Schepper B, Corthouts B, Van Oosterom AT. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors—an antiangiogenic effect? Anticancer Drugs. 1996;7(2):175–81.

    Article  PubMed  CAS  Google Scholar 

  67. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: a review. Digestion. 2000;62 Suppl 1:92–7.

    PubMed  CAS  Google Scholar 

  68. Kulke MH. Gastrointestinal neuroendocrine tumors: a role for targeted therapies? Endocr Relat Cancer. 2007;14(2):207–19.

    Article  PubMed  CAS  Google Scholar 

  69. Chan JA, Kulke MH. Progress in the treatment of neuroendocrine tumors. Curr Oncol Rep. 2009;11(3):193–9.

    Article  PubMed  CAS  Google Scholar 

  70. Yao JC. Neuroendocrine tumors. Molecular targeted therapy for carcinoid and islet-cell carcinoma. Best Pract Res Clin Endocrinol Metab. 2007;21(1):163–72.

    Article  PubMed  CAS  Google Scholar 

  71. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol. 2008;26(26):4311–8.

    Article  PubMed  Google Scholar 

  72. Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008;26(8):1316–23.

    Article  PubMed  CAS  Google Scholar 

  73. Hubina E, Nanzer AM, Hanson MR, Ciccarelli E, Losa M, Gaia D, et al. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours. Eur J Endocrinol. 2006;155(2):371–9.

    Article  PubMed  CAS  Google Scholar 

  74. Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46(6):723–34.

    Article  PubMed  Google Scholar 

  75. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007;21(1):111–29.

    Article  PubMed  CAS  Google Scholar 

  76. Fesinmeyer MD, Austin MA, Li CI, De Roos AJ, Bowen DJ. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1766–73.

    Article  PubMed  Google Scholar 

Download references

Conflict of Interest

No conflict of interest. Author(s) have nothing to disclose. All author(s) disclose that there are no potential conflicts (financial, professional, or personal) that are relevant to the manuscript.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Connecticut, Farmington, CT, 06032, USA

    Tarun Rustagi & Mridula Rai

  2. Department of Pathology, Saint Francis Hospital, Hartford, CT, USA

    Frank Bauer

Authors
  1. Tarun Rustagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mridula Rai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Bauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tarun Rustagi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rustagi, T., Rai, M. & Bauer, F. Non-functional Pancreatic Neuroendocrine Tumor as an Incidentaloma—A Case Report and Review of Literature. J Gastrointest Canc 44, 336–342 (2013). https://doi.org/10.1007/s12029-012-9445-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12029-012-9445-7

Keywords

Search

Navigation